HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Acotec Scientific / Equity Capital Markets

<p>With the acceleration of the aging process, the prevalence of various vascular diseases continue to rise, and related medical needs have increased dramatically. Among them, interventional therapy has been highly recognized by clinicians and patients with its advantages of less trauma, fewer complications, high safety and less patient pain, and the market demand shows a rapid growth. Therefore, many domestic innovative medical device enterprises accelerated the pace of listing in order to seize more market share. For example, according to the disclosure of the HKEX, <a href="https://www.smartkarma.com/entities/acotec-scientific-holdings-limited" target="_blank" data-smartkarma-citation="entities:32176:1" rel="noopener">Acotec Scientific Holdings (ASH HK)</a> applied to be listed on the main board on February 11, 2021. The following mainly include the insights on business, industry and financial position.</p>

With the acceleration of the aging process, the prevalence of various vascular diseases continue to rise, and related medical needs have increased dramatically. Among them, interventional therapy has been highly recognized by clinicians and patients with its advantages of less trauma, fewer complications, high safety and less patient pain, and the market demand shows a rapid growth. Therefore, many domestic innovative medical device enterprises accelerated the pace of listing in order to seize more market share. For example, according to the disclosure of the HKEX, Acotec Scientific Holdings (ASH HK) applied to be listed on the main board on February 11, 2021. The following mainly include the insights on business, industry and financial position.

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges

China

Acotec Scientific is a medical technology company specializing in the research, development, and application of innovative solutions for vascular diseases. Its core products include drug-coated balloons (DCB) and percutaneous transluminal angioplasty (PTA) balloon catheters, such as AcoArt Orchid & Dhalia. The company was founded in 2008 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acotec Scientific (6669 HK)

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges

This article analyzed Acotec Scientific in terms of its business, industry characteristics, financial position, and also include the concerns and...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)